A01=Michael Kremer
A01=Rachel Glennerster
Adjudication
Advisory Committee on Immunization Practices
Aid
Author_Michael Kremer
Author_Rachel Glennerster
Bill & Melinda Gates Foundation
Biotechnology
Bonus payment
Bribery
Budget
Calculation
Category=KCVJ
Category=KND
Category=MBGR
Category=MKG
Clinical trial
Consideration
Consumer
Copayment
Cost-effectiveness analysis
Credibility
Developed country
Developing country
Diphtheria
Disability-adjusted life year
Disease
Disease burden
Drug development
Efficacy
eq_bestseller
eq_business-finance-law
eq_isMigrated=1
eq_nobargain
eq_non-fiction
Expense
Externality
Funding
Health care
Health intervention
Health policy
Hepatitis B vaccine
HIV vaccine
Immunization
Incentive
Income
Institution
International AIDS Vaccine Initiative
Investor
Malaria
Malaria vaccine
Management of HIV/AIDS
Manufacturing cost
Marginal cost
Market (economics)
Market failure
Michael Kremer
Net present value
Payment
Pertussis
Pharmaceutical drug
Pharmaceutical industry
Poverty
Pricing
Private foundation (United States)
Private sector
Provision (accounting)
Requirement
Research and development
Schistosomiasis
Subsidy
Suggestion
Tax credit
Technology
Tetanus
Tuberculosis
UNICEF
Vaccination
Vaccination schedule
Vaccine
Working group
World Bank
Product details
- ISBN 9780691171166
- Weight: 255g
- Dimensions: 152 x 235mm
- Publication Date: 31 May 2016
- Publisher: Princeton University Press
- Publication City/Country: US
- Product Form: Paperback
Secure
checkout
Fast Shipping
Easy returns
Millions of people in the third world die from diseases that are rare in the first world--diseases like malaria, tuberculosis, and schistosomiasis. AIDS, which is now usually treated in rich countries, still ravages the world's poor. Vaccines offer the best hope for controlling these diseases and could dramatically improve health in poor countries. But developers have little incentive to undertake the costly and risky research needed to develop vaccines. This is partly because the potential consumers are poor, but also because governments drive down prices. In Strong Medicine, Michael Kremer and Rachel Glennerster offer an innovative yet simple solution to this worldwide problem: "Pull" programs to stimulate research. Here's how such programs would work. Funding agencies would commit to purchase viable vaccines if and when they were developed. This would create the incentives for vaccine developers to produce usable products for these neglected diseases. Private firms, rather than funding agencies, would pick which research strategies to pursue. After purchasing the vaccine, funders could distribute it at little or no cost to the afflicted countries.
Strong Medicine details just how these legally binding commitments would work. Ultimately, if no vaccines were developed, such a commitment would cost nothing. But if vaccines were developed, the program would save millions of lives and would be among the world's most cost-effective health interventions.
Michael Kremer is Gates Professor of Developing Societies at Harvard University, Senior Fellow at the Brookings Institution, and NonResident Fellow at the Center for Global Development. He founded and was the first executive director of WorldTeach, a nonprofit organization that places two hundred volunteer teachers annually in developing countries (1986-1989). He previously served as a teacher in Kenya. Rachel Glennerster is Director of the Poverty Action Lab at the Massachusetts Institute of Technology, a center devoted to evaluating the effectiveness of anti-poverty programs. She has worked on health and development policy at the UK Treasury, the Harvard Institute of International Development, and the International Monetary Fund.
